First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma.

被引：0
|
作者：
Kaufman, Jonathan [1 ]
Niesvizky, Ruben [2 ]
Stadtmauer, Edward A. [3 ]
Chanan-Khan, Asher [4 ]
Siegel, David [5 ]
Home, Heather [6 ]
Teoh, Nick [6 ]
Leoni, Matthew J. [6 ]
Wegener, William A. [6 ]
Goldenberg, David M. [6 ]
机构：
[1] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[6] Immunomedics Inc, Morris Plains, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1266 / 1267
页数：2
相关论文
共 50 条
  • [31] Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
    Wallace, Daniel J.
    Figueras, Florence
    Wegener, William A.
    Goldenberg, David M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) : 954 - 955
  • [32] Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.
    Alinari, Lapo
    Christian, Beth
    Yu, Bo
    Shin, Jungook
    Hertlein, Erin K.
    Lapalombella, Rosa
    Yan, Fengting
    Lesinski, Gregory
    Zhang, Xiaoli
    Lozanski, Gerard
    Muthusamy, Natarajan
    Goldenberg, David M.
    Byrd, John C.
    Baiocchi, Robert A.
    BLOOD, 2009, 114 (22) : 675 - 675
  • [33] Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells
    Hertlein, Erin K.
    Triantafillou, Georgia
    Hessler, Joshua
    Zhang, Xiaoli
    Jarjoura, David
    Lucas, David M.
    Lee, Robert J.
    Muthusamy, Natarajan
    Goldenberg, David M.
    Byrd, John C.
    BLOOD, 2009, 114 (22) : 301 - 301
  • [34] Safety and Tolerability of Anti-CD38 Monoclonal Antibodies (mAb) in Multiple Myeloma
    Thet, Aye
    Myint, Phyo Thazin
    Hadid, Tarik
    BLOOD, 2022, 140 : 12552 - 12553
  • [35] A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.
    Martin, Thomas G.
    Hsu, Karl
    Strickland, Stephen Anthony
    Glenn, Martha Jane
    Mikhael, Joseph
    Charpentier, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Anti-CD20 monoclonal antibody therapy in multiple myeloma
    Kapoor, Prashant
    Greipp, Patricia T.
    Morice, William G.
    Rajkumar, S. Vincent
    Witzig, Thomas E.
    Greipp, Philip R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) : 135 - 148
  • [37] CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
    Nishida, Hiroko
    Hayashi, Mutsumi
    Morimoto, Chikao
    Sakamoto, Michiie
    Yamada, Taketo
    BLOOD CANCER JOURNAL, 2018, 8
  • [38] CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
    Hiroko Nishida
    Mutsumi Hayashi
    Chikao Morimoto
    Michiie Sakamoto
    Taketo Yamada
    Blood Cancer Journal, 8
  • [39] Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin
    Chang, CH
    Sapra, P
    Vanama, SS
    Hansen, HJ
    Horak, ID
    Goldenberg, DM
    BLOOD, 2005, 106 (13) : 4308 - 4314
  • [40] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
    Richardson, P.
    Lokhorst, H.
    Palumbo, A.
    Nahi, H.
    Laubach, J.
    Gimsing, P.
    Lisby, S.
    Cakana, A.
    Brun, N. Constantin
    Plesner, T.
    DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
12345